Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 558 entries
Sorted by: Best Match Show Resources per page
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

World journal of hepatology

Purohit T, Cappell MS.
PMID: 25954476
World J Hepatol. 2015 May 08;7(7):926-41. doi: 10.4254/wjh.v7.i7.926.

Primary biliary cirrhosis (PBC) is an autoimmune, slowly progressive, cholestatic, liver disease characterized by a triad of chronic cholestasis, circulating anti-mitochondrial antibodies (AMA), and characteristic liver biopsy findings of nonsuppurative destructive cholangitis and interlobular bile duct destruction. About 10%...

Cite
Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol. 2015;7(7):926-41doi: 10.4254/wjh.v7.i7.926.
Purohit, T., & Cappell, M. S. (2015). Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World journal of hepatology, 7(7), 926-41. https://doi.org/10.4254/wjh.v7.i7.926
Purohit, Treta, and Cappell, Mitchell S. "Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy." World journal of hepatology vol. 7,7 (2015): 926-41. doi: https://doi.org/10.4254/wjh.v7.i7.926
Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol. 2015 May 08;7(7):926-41. doi: 10.4254/wjh.v7.i7.926. PMID: 25954476; PMCID: PMC4419097.
Copy Download .nbib Format: NLM
ABCB4 Disease Presenting with Cirrhosis and Copper Overload-Potential Confusion with Wilson Disease.

Journal of clinical and experimental hepatology

Shneider BL.
PMID: 25755323
J Clin Exp Hepatol. 2011 Sep;1(2):115-7. doi: 10.1016/S0973-6883(11)60131-X. Epub 2011 Nov 09.

A 2-year-old female with cirrhosis was found to have a liver copper of 248 μg/g dry weight. She was eventually diagnosed with ABCB4 disease on the basis of heterozygote A546D and R176W mutations. Her liver disease was partially responsive...

Cite
Shneider BL. ABCB4 Disease Presenting with Cirrhosis and Copper Overload-Potential Confusion with Wilson Disease. J Clin Exp Hepatol. 2011;1(2):115-7doi: 10.1016/S0973-6883(11)60131-X.
Shneider, B. L. (2011). ABCB4 Disease Presenting with Cirrhosis and Copper Overload-Potential Confusion with Wilson Disease. Journal of clinical and experimental hepatology, 1(2), 115-7. https://doi.org/10.1016/S0973-6883(11)60131-X
Shneider, Benjamin L. "ABCB4 Disease Presenting with Cirrhosis and Copper Overload-Potential Confusion with Wilson Disease." Journal of clinical and experimental hepatology vol. 1,2 (2011): 115-7. doi: https://doi.org/10.1016/S0973-6883(11)60131-X
Shneider BL. ABCB4 Disease Presenting with Cirrhosis and Copper Overload-Potential Confusion with Wilson Disease. J Clin Exp Hepatol. 2011 Sep;1(2):115-7. doi: 10.1016/S0973-6883(11)60131-X. Epub 2011 Nov 09. PMID: 25755323; PMCID: PMC3940549.
Copy Download .nbib Format: NLM
Amphiphilic calixresorcinarene associates as effective solubilizing agents for hydrophobic organic acids: construction of nano-aggregates.

Soft matter

Morozova JE, Syakaev VV, Kazakova EKh, Shalaeva YV, Nizameev IR, Kadirov MK, Voloshina AD, Zobov VV, Konovalov AI.
PMID: 27252123
Soft Matter. 2016 Jul 07;12(25):5590-9. doi: 10.1039/c6sm00719h. Epub 2016 Jun 02.

Here we represent the first example of the formation of mixed nanoscale associates, constructed from amphiphilic calixresorcinarenes and hydrophobic carboxylic acids including drugs. The amidoamino-calixresorcinarene self-associates effectively solubilize hydrophobic carboxylic acids - drugs such as naproxen, ibuprofen, ursodeoxycholic acid...

Cite
Morozova JE, Syakaev VV, Kazakova EKh, et al. Amphiphilic calixresorcinarene associates as effective solubilizing agents for hydrophobic organic acids: construction of nano-aggregates. Soft Matter. 2016;12(25):5590-9doi: 10.1039/c6sm00719h.
Morozova, J. E., Syakaev, V. V., Kazakova, E. K. h., Shalaeva, Y. V., Nizameev, I. R., Kadirov, M. K., Voloshina, A. D., Zobov, V. V., & Konovalov, A. I. (2016). Amphiphilic calixresorcinarene associates as effective solubilizing agents for hydrophobic organic acids: construction of nano-aggregates. Soft matter, 12(25), 5590-9. https://doi.org/10.1039/c6sm00719h
Morozova, Ju E, et al. "Amphiphilic calixresorcinarene associates as effective solubilizing agents for hydrophobic organic acids: construction of nano-aggregates." Soft matter vol. 12,25 (2016): 5590-9. doi: https://doi.org/10.1039/c6sm00719h
Morozova JE, Syakaev VV, Kazakova EKh, Shalaeva YV, Nizameev IR, Kadirov MK, Voloshina AD, Zobov VV, Konovalov AI. Amphiphilic calixresorcinarene associates as effective solubilizing agents for hydrophobic organic acids: construction of nano-aggregates. Soft Matter. 2016 Jul 07;12(25):5590-9. doi: 10.1039/c6sm00719h. Epub 2016 Jun 02. PMID: 27252123.
Copy Download .nbib Format: NLM
Physicochemical Properties of Ursodeoxycholic Acid Dispersed in Controlled Pore Glass.

Journal of colloid and interface science

Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K.
PMID: 10421735
J Colloid Interface Sci. 1999 Aug 15;216(2):276-284. doi: 10.1006/jcis.1999.6331.

The objective of this study was to reduce the crystallinity of ursodeoxycholic acid (UDCA) by solid dispersion with controlled pore glass (CPG). To evaluate the effect of pore diameter and pore volume of CPG on the crystalline properties of...

Cite
Okonogi S, Oguchi T, Yonemochi E, et al. Physicochemical Properties of Ursodeoxycholic Acid Dispersed in Controlled Pore Glass. J Colloid Interface Sci. 1999;216(2):276-284doi: 10.1006/jcis.1999.6331.
Okonogi, S., Oguchi, T., Yonemochi, E., Puttipipatkhachorn, S., & Yamamoto, K. (1999). Physicochemical Properties of Ursodeoxycholic Acid Dispersed in Controlled Pore Glass. Journal of colloid and interface science, 216(2), 276-284. https://doi.org/10.1006/jcis.1999.6331
Okonogi, et al. "Physicochemical Properties of Ursodeoxycholic Acid Dispersed in Controlled Pore Glass." Journal of colloid and interface science vol. 216,2 (1999): 276-284. doi: https://doi.org/10.1006/jcis.1999.6331
Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K. Physicochemical Properties of Ursodeoxycholic Acid Dispersed in Controlled Pore Glass. J Colloid Interface Sci. 1999 Aug 15;216(2):276-284. doi: 10.1006/jcis.1999.6331. PMID: 10421735.
Copy Download .nbib Format: NLM
End-stage Liver Disease in Children.

Current treatment options in gastroenterology

Squires RH.
PMID: 11560788
Curr Treat Options Gastroenterol. 2001 Oct;4(5):409-421. doi: 10.1007/s11938-001-0006-6.

The treatment of children with end-stage liver disease involves the coordinated management of nutritional deficiencies, ascites, pruritus, encephalopathy, and portal hypertension. The implementation of management strategies depends upon a parent or guardian to administer the plan in the context...

Cite
Squires RH. End-stage Liver Disease in Children. Curr Treat Options Gastroenterol. 2001;4(5):409-421doi: 10.1007/s11938-001-0006-6.
Squires, R. H. (2001). End-stage Liver Disease in Children. Current treatment options in gastroenterology, 4(5), 409-421. https://doi.org/10.1007/s11938-001-0006-6
Squires, Robert H.. "End-stage Liver Disease in Children." Current treatment options in gastroenterology vol. 4,5 (2001): 409-421. doi: https://doi.org/10.1007/s11938-001-0006-6
Squires RH. End-stage Liver Disease in Children. Curr Treat Options Gastroenterol. 2001 Oct;4(5):409-421. doi: 10.1007/s11938-001-0006-6. PMID: 11560788.
Copy Download .nbib Format: NLM
Synchronized disappearance of serum HCV-RNA, anti-U1 RNP, anti-La/SS-B, and anti-Scl-70 in a patient with chronic hepatitis.

Hepatology research : the official journal of the Japan Society of Hepatology

Omagari K, Matsuo I, Ohba K, Masuda J, Hazama H, Sakimura K, Kinoshita H, Tsurutani H, Isomoto H, Murase K, Kohno S.
PMID: 11251309
Hepatol Res. 2001 Mar 26;19(3):263-269. doi: 10.1016/s1386-6346(00)00114-5.

The authors report a rare case of chronic hepatitis in whom normalization of serum aminotransferases was associated with disappearance of serum hepatitic C virus (HCV)-ribonucleic acid (RNA), anti-U1 RNP, anti-La/SS-B, and anti-Scl-70 antibodies without treatment of interferon or corticosteroids....

Cite
Omagari K, Matsuo I, Ohba K, et al. Synchronized disappearance of serum HCV-RNA, anti-U1 RNP, anti-La/SS-B, and anti-Scl-70 in a patient with chronic hepatitis. Hepatol Res. 2001;19(3):263-269doi: 10.1016/s1386-6346(00)00114-5.
Omagari, K., Matsuo, I., Ohba, K., Masuda, J., Hazama, H., Sakimura, K., Kinoshita, H., Tsurutani, H., Isomoto, H., Murase, K., & Kohno, S. (2001). Synchronized disappearance of serum HCV-RNA, anti-U1 RNP, anti-La/SS-B, and anti-Scl-70 in a patient with chronic hepatitis. Hepatology research : the official journal of the Japan Society of Hepatology, 19(3), 263-269. https://doi.org/10.1016/s1386-6346(00)00114-5
Omagari, K, et al. "Synchronized disappearance of serum HCV-RNA, anti-U1 RNP, anti-La/SS-B, and anti-Scl-70 in a patient with chronic hepatitis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 19,3 (2001): 263-269. doi: https://doi.org/10.1016/s1386-6346(00)00114-5
Omagari K, Matsuo I, Ohba K, Masuda J, Hazama H, Sakimura K, Kinoshita H, Tsurutani H, Isomoto H, Murase K, Kohno S. Synchronized disappearance of serum HCV-RNA, anti-U1 RNP, anti-La/SS-B, and anti-Scl-70 in a patient with chronic hepatitis. Hepatol Res. 2001 Mar 26;19(3):263-269. doi: 10.1016/s1386-6346(00)00114-5. PMID: 11251309.
Copy Download .nbib Format: NLM
Primary Sclerosing Cholangitis.

Current treatment options in gastroenterology

Lee YM, Kim DJ.
PMID: 11696273
Curr Treat Options Gastroenterol. 2001 Dec;4(6):469-477. doi: 10.1007/s11938-001-0012-8.

There is no proven medical therapy for primary sclerosing cholangitis. The goal of management should be treatment of symptoms and complications of cholestasis, as well as attempts at treating the underlying disease process. In addition, efforts should be made...

Cite
Lee YM, Kim DJ. Primary Sclerosing Cholangitis. Curr Treat Options Gastroenterol. 2001;4(6):469-477doi: 10.1007/s11938-001-0012-8.
Lee, Y. M., & Kim, D. J. (2001). Primary Sclerosing Cholangitis. Current treatment options in gastroenterology, 4(6), 469-477. https://doi.org/10.1007/s11938-001-0012-8
Lee, Young-Mee, and Kim, David J.. "Primary Sclerosing Cholangitis." Current treatment options in gastroenterology vol. 4,6 (2001): 469-477. doi: https://doi.org/10.1007/s11938-001-0012-8
Lee YM, Kim DJ. Primary Sclerosing Cholangitis. Curr Treat Options Gastroenterol. 2001 Dec;4(6):469-477. doi: 10.1007/s11938-001-0012-8. PMID: 11696273.
Copy Download .nbib Format: NLM
[PRIMARY SCLEROSING CHOLANGITIS].

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru

Dantas W.
PMID: 12140588
Rev Gastroenterol Peru. 2000 Jul-Sep;20(3):270-284.

Primary sclerosing cholangitis (PSC) is a chronic cholestatic and progressive disease, of unknown etiology, characterized by inflammation and fibrosis of intra-hepatic and extra-hepatic biliary tree. Two thirds of the patients have, simultaneously, ulcerative colitis (UC); on the other hand,...

Cite
Dantas W. Colangite esclerosante primaria. [PRIMARY SCLEROSING CHOLANGITIS]. Rev Gastroenterol Peru. 2000;20(3):270-284
Dantas, W. (2000). Colangite esclerosante primaria. [PRIMARY SCLEROSING CHOLANGITIS]. Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, 20(3), 270-284.
Dantas, Waldomiro. "Colangite esclerosante primaria." [PRIMARY SCLEROSING CHOLANGITIS]. Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru vol. 20,3 (2000): 270-284.
Dantas W. Colangite esclerosante primaria. [PRIMARY SCLEROSING CHOLANGITIS]. Rev Gastroenterol Peru. 2000 Jul-Sep;20(3):270-284. Spanish. PMID: 12140588.
Copy Download .nbib Format: NLM
Ursodeoxycholic acid: Mechanism of action and novel clinical applications.

Hepatology research : the official journal of the Japan Society of Hepatology

Ikegami T, Matsuzaki Y.
PMID: 18034825
Hepatol Res. 2008;38(2):123-31. doi: 10.1111/j.1872-034X.2007.00297.x. Epub 2007 Nov 23.

Ursodeoxycholic acid (UDCA) is used in the treatment of cholestatic liver diseases, gallstone dissolution, and for patients with hepatitis C virus infection to ameliorate elevated alanine aminotransferase levels. The efficacy of UDCA treatment has been debated and the mechanisms...

Cite
Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res. 2007;38(2):123-31doi: 10.1111/j.1872-034X.2007.00297.x.
Ikegami, T., & Matsuzaki, Y. (2008). Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatology research : the official journal of the Japan Society of Hepatology, 38(2), 123-31. https://doi.org/10.1111/j.1872-034X.2007.00297.x
Ikegami, Tadashi, and Matsuzaki, Yasushi. "Ursodeoxycholic acid: Mechanism of action and novel clinical applications." Hepatology research : the official journal of the Japan Society of Hepatology vol. 38,2 (2008): 123-31. doi: https://doi.org/10.1111/j.1872-034X.2007.00297.x
Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res. 2008;38(2):123-31. doi: 10.1111/j.1872-034X.2007.00297.x. Epub 2007 Nov 23. PMID: 18034825.
Copy Download .nbib Format: NLM
Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?.

Nature clinical practice. Gastroenterology & hepatology

Chazouillères O, Corpechot C.
PMID: 16673001
Nat Clin Pract Gastroenterol Hepatol. 2006 May;3(5):248-9. doi: 10.1038/ncpgasthep0493.

No abstract available.

Cite
Chazouillères O, Corpechot C. Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?. Nat Clin Pract Gastroenterol Hepatol. 2006;3(5):248-9doi: 10.1038/ncpgasthep0493.
Chazouillères, O., & Corpechot, C. (2006). Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?. Nature clinical practice. Gastroenterology & hepatology, 3(5), 248-9. https://doi.org/10.1038/ncpgasthep0493
Chazouillères, Olivier, and Corpechot, Christophe. "Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?." Nature clinical practice. Gastroenterology & hepatology vol. 3,5 (2006): 248-9. doi: https://doi.org/10.1038/ncpgasthep0493
Chazouillères O, Corpechot C. Is high-dose ursodeoxycholic acid effective for the treatment of patients with primary sclerosing cholangitis?. Nat Clin Pract Gastroenterol Hepatol. 2006 May;3(5):248-9. doi: 10.1038/ncpgasthep0493. PMID: 16673001.
Copy Download .nbib Format: NLM
Cholestatic syndromes.

Current opinion in gastroenterology

Trauner M, Boyer JL.
PMID: 17033302
Curr Opin Gastroenterol. 2002 May;18(3):314-29. doi: 10.1097/00001574-200205000-00005.

Further insights into the molecular regulation of bile acid transport and metabolism have provided the basis for a better understanding of the pathogenesis of cholestatic liver diseases. Novel insights into the mechanisms of action of ursodeoxycholic acid should advance...

Cite
Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin Gastroenterol. 2002;18(3):314-29doi: 10.1097/00001574-200205000-00005.
Trauner, M., & Boyer, J. L. (2002). Cholestatic syndromes. Current opinion in gastroenterology, 18(3), 314-29. https://doi.org/10.1097/00001574-200205000-00005
Trauner, Michael, and Boyer, James L. "Cholestatic syndromes." Current opinion in gastroenterology vol. 18,3 (2002): 314-29. doi: https://doi.org/10.1097/00001574-200205000-00005
Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin Gastroenterol. 2002 May;18(3):314-29. doi: 10.1097/00001574-200205000-00005. PMID: 17033302.
Copy Download .nbib Format: NLM
Clinical characteristics of autoimmune hepatitis in older aged patients.

Hepatology research : the official journal of the Japan Society of Hepatology

Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S, Furukawa E, Ikeda R, Okita S, Okada T, Yoshida O, Murata Y, Akbar SM, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M.
PMID: 16872893
Hepatol Res. 2006 Oct;36(2):139-42. doi: 10.1016/j.hepres.2006.06.007. Epub 2006 Jul 26.

BACKGROUND AND AIMS: Autoimmune hepatitis (AIH) is an inflammatory disease of the liver that usually develops in middle-aged women. However, due to the increasing aging of the population and better diagnostic facilities, AIH is now diagnosed in older patients...

Cite
Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res. 2006;36(2):139-42doi: 10.1016/j.hepres.2006.06.007.
Miyake, T., Miyaoka, H., Abe, M., Furukawa, S., Shigematsu, S., Furukawa, E., Ikeda, R., Okita, S., Okada, T., Yoshida, O., Murata, Y., Akbar, S. M., Matsuura, B., Michitaka, K., Horiike, N., Hiasa, Y., & Onji, M. (2006). Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatology research : the official journal of the Japan Society of Hepatology, 36(2), 139-42. https://doi.org/10.1016/j.hepres.2006.06.007
Miyake, Teruki, et al. "Clinical characteristics of autoimmune hepatitis in older aged patients." Hepatology research : the official journal of the Japan Society of Hepatology vol. 36,2 (2006): 139-42. doi: https://doi.org/10.1016/j.hepres.2006.06.007
Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S, Furukawa E, Ikeda R, Okita S, Okada T, Yoshida O, Murata Y, Akbar SM, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res. 2006 Oct;36(2):139-42. doi: 10.1016/j.hepres.2006.06.007. Epub 2006 Jul 26. PMID: 16872893.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 558 entries